Observational studyMedicine2018
Evaluation of willingness to pay per quality-adjusted life year for a cure: A contingent valuation method using a scenario-based survey.
Observational study in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Valuation of Treatments for Rare Diseases: A Systematic Literature Review of Societal Preference Studies.Advances in therapy · 2023Pooled it
- Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression.The European journal of health economics : HEPAC : health economics in prevention and care · 2022Pooled it
- Pooled it
- Willingness to pay for a quality adjusted life year across different time horizons: direct elicitation in Quebec.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Cost-utility analysis of traditional Korean medicine without acupuncture claims versus integrative care for menopausal disorders: A nationwide retrospective cohort study.Integrative medicine research · 2026Article
- Assessment of cost-effectiveness threshold using a double-bounded dichotomous choice model.Public health in practice (Oxford, England) · 2026Article
- Cost-effectiveness analysis of extended endoscopic lumbar foraminotomy (EELF) and transforaminal lumbar interbody fusion (TLIF): a prospective observational study.Scientific reports · 2025Observational
- Information and Communications Technology-Based Monitoring Service for Tailored Chronic Disease Management in Primary Care: Cost-Effectiveness Analysis Based on ICT-CM Trial Results.Journal of medical Internet research · 2024Article
- Cost-effectiveness analysis of dupilumab among patients with uncontrolled severe asthma using LIBERTY ASTHMA QUEST Korean data.Health economics review · 2024Article
- Eligibility and Cost-Utility Analysis of Dapagliflozin in Patients with Heart Failure Across the Whole Spectrum of Ejection Fraction in South Korea.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024Article
- Real-World Eligibility and Cost-Effectiveness Analysis of Empagliflozin for Heart Failure in Korea.Journal of Korean medical science · 2024Article
- The effects of herbal medicine (Jujadokseo-hwan) on quality of life in patients with mild cognitive impairment: Cost-effectiveness analysis alongside randomized controlled trial.Integrative medicine research · 2023Article
- Cost-Effectiveness Analysis of Germline and SomaticAnnals of laboratory medicine · 2023Article
- The Primary Process and Key Concepts of Economic Evaluation in Healthcare.Journal of preventive medicine and public health = Yebang Uihakhoe chi · 2022Article
- Cost Utility Analysis of a Pilot Study for the Korean Lung Cancer Screening Project.Cancer research and treatment · 2022Article
- Assessing the Optimality of a COVID Lockdown in the United States.Economics of disasters and climate change · 2021Article
- Cost-effectiveness of Bariatric Surgery for People with Morbid Obesity in South Korea.Obesity surgery · 2020Article
- An exploratory study to estimate cost-effectiveness threshold value for life saving treatments in western Iran.Cost effectiveness and resource allocation : C/E · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cost-effectiveness is 1 of the most important factors in medicine reimbursement, and social willingness to pay (WTP) can provide evidence for the threshold of cost-effectiveness analysis. Recently, the concept of curative medicines has been introduced, so it is necessary to study their cost-effectiveness. This study aimed to estimate WTP per quality-adjusted life year (QALY) for a cure in the Korean general population.A total of 507 people from the general population, proportionally assigned by sex, age, and region, participated in face-to-face interviews. The contingent valuation survey was conducted with scenarios involving 4 EuroQol-5 dimensions (EQ-5D) with different health statuses. We assumed a treatment that moved the health status of each scenario to perfect health. WTP for 1 year of treatment was derived using a double-bounded format followed by open-ended answers. In the cure scenario, the post-treatment effect continued for a lifetime; in the non-cure scenario, the effect instantly stopped when treatment was terminated. Additionally, prolonged treatment effects lasting 5 and 10 years were added. To identify the factors influencing WTP, a multi-level analysis was performed.WTP per QALY for the non-cure scenario was KRW 15 million/QALY. For the cure scenario, WTP was 2.3 times higher (KRW 35 million/QALY) than in the non-cure scenario. The results for the prolonged treatment effect scenarios were KRW 22 million/QALY and KRW 27 million/QALY, which are 1.4 and 1.8 times higher than the non-cure scenario, respectively. In all scenarios, the statistically significant factors affecting WTP per QALY were higher education, higher household income, and healthcare provider.This study revealed that WTP for a cure treatment was higher than that for non-cure; this higher WTP should be considered in future decision-making regarding curative treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.